Optimal and Safe Pain Management Approach in Ankle and Hindfoot Fractures:

- 2 Improving Practitioner Decision
- 3 Short title: Ankle and Hindfoot Fractures Effective and Safe Pain Control
- 4 Dr. Tashfeen Ahmad
- 5 FCPS, PhD

- 6 Assistant Professor
- 7 Departments of Surgery and Biological & Biomedical Sciences
- 8 Aga Khan University, Karachi, Pakistan
- 9 Contact e-mail: <u>tashfeen.ahmad@aku.edu</u>
- 10 Contact Number: +92-21-34864742
- 11 Dr. Zehra Abdul Muhammad
- 12 M.B.B.S., M.S.
- 13 Senior Instructor (Research)
- 14 Department of Surgery
- 15 Aga Khan University
- 16 Contact e-mail: <u>zehra.abdul@aku.edu</u>
- 17 Contact Number: +92-21-34864746
- 18 Dr. Yasir Mohib
- 19 M.B.B.S., FCPS
- 20 Assistant Professor
- 21 Departments of Surgery
- 22 Aga Khan University, Karachi, Pakistan
- 23 Contact e-mail: yasir.mohib@aku.edu
- 24 Contact Number: +92-21-34864350
- 25 Dr. Riaz Hussain

- 26 M.B.B.S., FCPS
- 27 Associate Professor
- 28 Departments of Surgery
- 29 Aga Khan University, Karachi, Pakistan
- 30 Contact e-mail: riaz.lakdawala@aku.edu
- 31 Contact Number: +92-21-34864753
- 32 Dr. Masood Umer
- 33 M.B.B.S., FCPS
- 34 Professor & Section Head
- 35 Departments of Surgery
- 36 Aga Khan University, Karachi, Pakistan
- 37 Contact e-mail: masood.umer@aku.edu
- 38 Contact Number: +92-21-34864736
- 39 Corresponding Author:
- 40 Dr. Zehra Abdul Muhammad
- 41 M.B.B.S., M.S.
- 42 Senior Instructor (Research)
- 43 Department of Surgery
- 44 The Aga Khan University
- 45 Stadium Road, P.O. Box 3500
- 46 Karachi 74800, Pakistan

- 47 Contact e-mail: zehra.abdul@aku.edu
- 48 Contact Number: +92-21-34864746, +92 3212198901

Author contributions: Dr. Tashfeen Ahmad and Dr. Zehra Abdul Muhammad contributed to the study Data interpretation and critical manuscript review, Dr. Zehra Abdul Muhammad contributed to the study design, concept, questionnaire design, Literature search, data collection with analysis, manuscript writing, data interpretation, Dr. Yasir Mohib, Dr. Riaz Hussain, and Dr. Masood Umer provided feedback with a critical manuscript review.

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

Abstract Background: Over or sub-optimal analgesic treatment leads to undesired consequences and patient dissatisfaction. The study aims to assess the sub-optimal or optimal pain relief and safety of routinely prescribed oral analgesic(s) at discharge and 1-week post-discharge in ankle and foot fracture surgeries. **Methods:** The ongoing prospective cohort study data on 54 ankle and hindfoot trauma fracture adult patients enrolled between June 2022 to July 2023 was analyzed. Post-surgery oral analgesics prescribed at hospital discharge and 1-week follow-up were stratified for assessing adverse events and pain (Visual Analogue Scale) at 1- and 2 weeks post-discharge. The relationship of age, gender, and comorbidity was analyzed by multiple logistic regression for adverse events and multiple linear regression for pain score. **Results:** Median pain scores at 1- and 2-week follow-ups were 3.2 (IQR=3.0) and 2 (IQR=2.0) respectively. Combinations of tramadol, acetaminophen with naproxen or diclofenac or orphenadrine; and naproxen, pregabalin, with acetaminophen seemed toxic with sub-optimal pain control. Similar results were for celecoxib combined with pregabalin and etoricoxib combined with diclofenac or tramadol. Acetaminophen alone was safe but occasionally showed intolerance. Etoricoxib or diclofenac alone or with acetaminophen was safe and showed better pain control in this cohort. A regression model was non-significant for a relationship between covariates and pain scores or adverse events. Conclusion: Current data suggests that certain oral analgesics or their combinations are harmful with sub-optimal pain control while some are safe and effective. Choosing suitable analgesics or their combinations in specific fractures might reduce patient harm with optimal pain management.

- 78 Keywords: Ankle fracture, Hindfoot fracture, Trauma, Optimal pain management, Adverse
- 79 events, Oral analgesics.

Introduction:

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

The ankle and hindfoot are essential anatomical parts for controlling body balance, and mobility. If fractured, there is difficulty in ambulation and fracture pain further restricts these movements. Fracture pre-and post-treatment pain control is essential to reduce patient distress, but over or suboptimal treatment leads to undesired consequences and results in readmissions, prolonged treatment, and patient dissatisfaction. Further to this, while selecting analgesics, pain control is mainly focused, ignoring potential patient harm. Parenteral analgesics are usually switched to oral analgesics at the time of hospital discharge to control pain for ambulation and rehabilitation. To optimize pain management, it is of utmost importance to choose analgesics that timely and adequately manage pain and have negligible side effects. There is scarce data available on optimal pain management (including pain relief as well as analgesic safety) for specific fractures in adults [1-6]. Some pain management standards like The National Institute for Health and Care Excellence (NICE) guideline, Centers for Disease Control and Prevention (CDC), and some research studies recommend acetaminophen as the first treatment choice followed by either NSAIDs or opioids depending on fracture type, site, etc. [7, 8]. In the NICE guide, pain management for ankle and foot fractures is also specified. Oral acetaminophen is recommended as an initial treatment for ankle fractures. Codeine could be added for uncontrolled pain with further addition of NSAIDs as required but with due care in elderly and frail adults [7]. Injectable morphine might be administered in uncontrolled ankle fracture pain with special attention in elderly and frail adults [7, 9]. Furthermore, certain research studies developed ankle and foot fracture pain management protocols with a reduced number of analgesic quantities while in some studies patient satisfaction with better ankle fracture pain control was assessed [1012]. Some randomized controlled trials were performed to assess safety and pain control by certain analgesics in ankle and foot fracture surgeries [13, 14].

It is essential that practitioners have sound knowledge about appropriate analgesic selection that controls pain effectively and is safe. The study aims to assess the extent of pain relief and safety of oral analgesic(s) routinely prescribed in ankle and foot fracture surgeries at discharge and 1-week post-discharge at a tertiary care hospital. This will allow us to identify the analgesics or their combinations that either adequately control pain with better tolerance or inadequately control pain with potential toxicity. The current evidence will help maximize benefit and reduce patient harm by selecting appropriate and safe analgesics for ankle and hind foot trauma fracture pain management and thus, optimize orthopaedic surgeons analgesic prescribing practice.

Methods:

After obtaining Ethical Review Committees and Institutional approvals, the observational, prospective cohort study was initiated in June 2022. The adult patient population with ankle or hindfoot trauma fractures of any gender who arrived at a tertiary care hospital between June 2022 to July 2023 and were surgically managed were included. Those patients who were unable to consent or had undergone limb amputation were excluded. The patient's written informed consent was obtained as per Good Clinical Practice guidelines before study enrollment. The demographics and prescribed oral analgesics at patient discharge and 1-week follow-up were recorded. Continuous variables like for age, normality of distribution was assessed for normality of distribution using the Shapiro Wilk test. For qualitative variables, frequency and percentages were used. Patients were followed at 1- and 2-week post-discharge to assess their pain control using a visual analogue scale (0=no pain, 1-3=mild, 4-6=moderate, and 7-10=severe pain scores) as well

as any adverse events (reported by patients or were clinically examined/identified) likely with prescribed oral analgesics at discharge and 1-week follow-up respectively. Oral analgesics or their combinations prescribed at discharge and 1-week follow-up were stratified. Analgesics with sub-optimal pain control and toxicity or with optimal pain control and tolerance were isolated. The relationship of covariates age gender, and comorbid condition was evaluated between adverse events or pain scores assessed at 1- and 2-week follow-ups using multiple logistic regression or multiple linear regression analysis respectively. The *p*-value <0.05 was considered statistically significant with a confidence interval of 95%.

Results:

126

127

128

129

130

131

132

133

134

135

During almost one year time, 54 ankle and hindfoot fracture patients were enrolled in the study in 136 which ankle fractures 46 (85%), hindfoot 7 (13%), and both ankle and hindfoot fractures 01 (2%). 137 Males were 33 (61%) while females were 21 (39%). The median age was 46 (IQR=25). The most 138 common mechanisms of injury were falls (N=24, 44%) and road traffic accidents (N=23, 43%). 139 Median pain scores were 3.2 (IQR=3.0) and 2.0 (IQR=2.0) at 1- and 2-week follow-ups 140 respectively. 141 At 1 week follow-up, 25 (46%) patients were free of any AE/SAE while 29(54%) experienced 142 either AE (N=17) or SAE (N=12) potentially due to analgesics prescribed at the time of discharge. 143 At 2 weeks follow-up, 38(70%) patients were free of AE/SAE while 16(30%) experienced either 144 145 AE (N=12) or SAE (N=04) potentially due to 1-week prescribed analgesics. No mortality was reported at both follow-ups. 146 On stratification (Figures 1 and 2), the prescribed analgesics showing toxicity and with sub-147 148 optimal pain control or analgesics showing better pain control and tolerance at 1- and 2-week

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

follow-ups were segregated. It was observed that analgesic combinations like the combination of acetaminophen, tramadol, and diclofenac (N=8) showed several SAEs (N=3) and AE (N=2) with moderate pain in half of the patients at follow-ups. Naproxen, acetaminophen, and pregabalin with or without adding thiocolchicoside or tizanidine (N=3) showed SAE (N=1) or AE (N=1) with mostly moderate pain. Adding tramadol in the analgesic combination naproxen, acetaminophen, and pregabalin (N=2) shows AE (N=1) and mild/moderate pain. Combining naproxen, acetaminophen, and tramadol (N=2) also showed AE in both patients with mild/severe pain. Figure 1: Discharge analysis with potential SAE/AEs (A) and pain control (B). Figure 2: Analgesics prescribed at 1-week follow-up with potential SAE/AEs (A) and pain control (B). Patients treated with the combination of acetaminophen and orphenadrine with or without adding tramadol (N=5) experienced SAE (N=3) and AE (N=1) with inadequate pain control in the majority at follow-ups. Combination of celecoxib, and acetaminophen (N=4) showed AE (N=2) and no to moderate pain. If celecoxib was combined with pregabalin or tramadol (N=3) showed AE (N=2) with severe pain (N=2). Meloxicam when administered alone (N=4) showed SAE (N=1) and AE (N=2) with none to moderate pain. When meloxicam was combined with tramadol and acetaminophen (N=2) showed no AE with mild/moderate pain (N=2). Tramadol, when combined with acetaminophen (N=9) produced AEs (N=4) but pain was well controlled in these patients at follow-ups.

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

Some analgesics in certain analgesic combinations worked well while when combined with some other analgesics showed toxicity and inadequate pain control. Analgesic etoricoxib (N=2) had no AE/SAE and no/mild pain. Adding acetaminophen in etoricoxib (N=1) showed no AE/SAE but moderate pain. If etoricoxib was combined with tramadol or diclofenac (N=3) showed SAE (N=1) or AE (N=1) with no to moderate pain. Patients treated with diclofenac with or without acetaminophen (N=7) experienced only mild AE (N=2) with no/mild pain in the majority. Acetaminophen (N=6) administration showed SAE (N=1) with no to moderate pain. The combination of pregabalin and acetaminophen (N=5) with or without tramadol showed no SAE/AE and pain was none or mild in the majority. On applying multiple logistic regression, the model was non-significant for AEs assessed at 1- $(X^{2}(3) = 0.47, p=0.9)$ and 2 weeks $(X^{2}(3) = 3.9, p=0.26)$ to covariates age (p=0.9, 0.6), gender (p=0.7, 0.6), and comorbidity binary variable (p=0.6, 0.2) with Nagelkerke R²=0.01 and 0.1, respectively. The multiple linear regression model was non-significant for pain score at 1- and 2week follow-ups and covariates age (p=0.1, CI= -0.67-0.13; p=0.9, CI= -0.03-0.03), gender (p=0.7, CI= -1.2-0.9; p=0.1, CI= -1.6-0.2), and comorbidity binary variable (p=0.1, CI= -0.2-2.3; p=0.2, CI = -0.4 - 1.8) with $R^2 = 0.05$ and 0.07 respectively. **Discussion:**

In the current data, it was observed that some oral analgesics prescribed to ankle or hindfoot fracture patients at discharge or at 1-week follow-up are sub-optimal in controlling pain and showed toxicity at 1- and/or 2-week follow-ups respectively. When acetaminophen, tramadol, and diclofenac were combined, several central nervous system (CNS) and cardiovascular side effects were reported like anxiety, insomnia, headache, dizziness, angina, hypotension, hypertension, etc.

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

with sub-optimal pain control. In the literature, diclofenac risks are reported, particularly cardiovascular events [15, 16]. Additionally, some evidence shows that combining tramadol and diclofenac can cause CNS and GIT side effects but contrary to our findings, better analgesia was observed in these studies [17-19]. Another combination of naproxen, acetaminophen pregabalin with or without adding other analgesics like thiocolchicoside or tizanidine or tramadol showed sub-optimal pain control with GIT, cardiovascular (CVS), and CNS toxicity like hypotension, headache, anorexia, dysphagia, constipation, oral ulcers, diarrhea, weakness, cough etc. Similar reports are available on tramadol and naproxen toxicity and sub-optimal pain control on opioid use [20-27]. In addition to the above analgesic combinations, acetaminophen and orphenadrine including or not tramadol showed suboptimal pain control with toxicity like hypotension, hypertension, dyspnea, sweating, dysuria, anorexia, depression, etc. There is scarce literature available on the toxicity of this combination [28]. When celecoxib and acetaminophen were combined showed better pain control in the majority and produced gastrointestinal (GIT) side effects like constipation, nausea, and vomiting. The addition of pregabalin in this combination produced CNS and GIT side effects like insomnia, constipation, diarrhea, etc. with sub-optimal pain control. Our finding is contrary to available scarce evidence of celecoxib with pregabalin being safe and effective in spinal surgery [29]. As the indication of pain management is different, the results may vary. Celecoxib toxicity is also reported for CNS, GIT, and CVS systems [30, 31]. Meloxicam when taken alone, one 30-year-old patient experienced SAE hypotension with no underlying comorbidity. Besides this, GIT-related side effects were also observed in patients like

constipation and diarrhea. The pain was mostly well controlled. The side effects of meloxicam are commonly related to GIT problems, but cerebrovascular side effects are also known [32-34]. Etoricoxib when combined with acetaminophen was safe with no side effects and better pain control in ankle and hind foot fractures but when tramadol or diclofenac is added, the combination showed severe CNS toxicity like memory loss, blurred vision, fatigue, dry mouth along with GIT problems like anorexia, constipation, nausea with sub-optimal pain control. Few reports are available for this combination in which side effects of etoricoxib when combined with diclofenac are mentioned like GIT and CNS problems including seizures, hypertension, etc. [35-38] Analgesic pregabalin alone or with acetaminophen and tramadol showed no AE with none to moderate pain. Rare reports are available for this combination which showed better pain control with AEs like somnolence, dizziness, and blurred vision [39]. In the literature, acetaminophen is reported to be a safe analgesic [40, 41]. In the present research, mostly there was no harm observed after acetaminophen administration except for one 24-yearold pregnant lady with no underlying comorbidity who experienced hypotension. It was also observed that pain control was sub-optimal with acetaminophen alone. The literature reports similar systemic events including hypotension after taking acetaminophen [42-48]. In our ankle and hindfoot fracture population, analgesic diclofenac with or without acetaminophen optimally controlled pain as well as was safe in ankle and hindfoot fractures. When diclofenac was combined with tramadol showed SAE/AEs but when prescribed alone or in combination with acetaminophen, it seemed safe and had better pain control.

Conclusion:

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

Thus, in the current ankle and hindfoot fractures data on oral analgesics management, it was observed that certain analgesic combinations were sub-optimal in controlling pain and were toxic like combinations of tramadol with diclofenac/naproxen; naproxen, pregabalin and acetaminophen; etoricoxib with tramadol/diclofenac; orphenadrine with acetaminophen with or without tramadol; and celecoxib with acetaminophen with or without tramadol/pregabalin. Changing some sets of analgesic combinations were safe and had better pain control like etoricoxib or diclofenac with or without combining with acetaminophen showed better tolerance and pain control in ankle and hindfoot fracture patients. The current stratification of harmful and safe analgesic combinations might assist in optimal pain management of specific fractures by selecting safe analgesics that have better pain control.

Limitation:

238

239

240

241

242

243

244

245

246

247

248

249

250

252

253

256

257

260

- This is a single-center study and thus, the generalizability of findings was not achieved. The
- analgesics to AE relationship was not determined thoroughly by root cause analysis.

Disclosure:

- 254 The authors report no proprietary or commercial interest in any product mentioned or concept
- 255 discussed in this article.

Funding:

- The study was generously supported by the Orthopaedic Trauma Association (proposal ID #6704,
- 259 https://ota.org/). The award was received by TA, ZM, and YM.

Conflict of interest:

261

263

264

266

267

The Authors declare that there are no conflicts of interest regarding the publication of this article.

Data availability:

265 On reasonable request, data will be provided.

References:

- 1. Drendel AL, Gorelick MH, Weisman SJ, Lyon R, Brousseau DC, Kim MK. A randomized
- clinical trial of ibuprofen versus acetaminophen with codeine for acute pediatric arm fracture
- pain. Ann Emerg Med. 2009;54(4): 553-560.
- 271 2. Charney RL, Yan Y, Schootman M, Kennedy RM, Luhmann JD. Oxycodone versus codeine
- for triage pain in children with suspected forearm fracture: a randomized controlled trial.
- 273 Pediatr Emerg Care. 2008;24(9): 595-600.
- 3. Friday JH, Kanegaye JT, McCaslin I, Zheng A, Harley JR. Ibuprofen provides analgesia
- equivalent to acetaminophen-codeine in the treatment of acute pain in children with extremity
- injuries: a randomized clinical trial. Acad Emerg Med. 2009;16(8): 711-716.
- 277 4. Clark E, Plint AC, Correll R, Gaboury I, Passi B. A randomized, controlled trial of
- acetaminophen, ibuprofen, and codeine for acute pain relief in children with musculoskeletal
- 279 trauma. Pediatrics. 2007;119(3): 460-467.
- 5. Benhamed A, Boucher V, Emond M. Pain management in emergency department older adults
- with pelvic fracture: still insufficient. Canadian Journal of Emergency Medicine. 2022;24(3):
- 282 245-246.

- 283 6. Apostolopoulos A, Kiriakidis A, Xrisanthopoulou M, Anastasopoulos P, Antoniou D, Liakou
- 284 K, et al. Parecoxib as a post surgical analgesic drug in fractures of the hip joint in comparison
- with diclofenac-pethidine. Orthop Procs. 2006;88–B Suppl 1:186
- 7. NICE. Fractures (non-complex): assessment and management; 2016 [cited 2022 October 12].
- 287 Available from:
- https://www.nice.org.uk/guidance/NG38/chapter/Recommendations#ongoing-orthopaedic-
- 289 management.
- 8. Centers for Disease Control and Prevention (CDC) guidelines for prescribing opioids for pain
- United States; 2022 2023 [updated January 31, 2023; cited 2023 March 27]. Available from:
- 292 https://www.guidelinecentral.com/guideline/2214777/.
- 9. NICE. Complex fractures; 2016 [cited 2023 April 06]. Available from:
- https://www.nice.org.uk/guidance/ng37/resources/fractures-complex-assessment-and-
- 295 management-pdf-1837397402053.
- 296 10. Troy Boffeli D, Catlea Gorman D. A guide to postoperative pain management. Podiatry
- 297 Today. 2018;31(9).
- 298 11. Xu AL, Humbyrd CJ. Strategies for Reducing Perioperative Opioid Use in Foot and Ankle
- Surgery: Education, Risk Identification, and Multimodal Analgesia. Orthopedic Clinics. 2023.
- 12. Helmerhorst GTT, Lindenhovius ALC, Vrahas M, Ring D, Kloen P. Satisfaction with pain
- relief after operative treatment of an ankle fracture. Injury. 2012;43(11): 1958-1961.
- 302 13. Jarde O, Boccard E. Parenteral versus Oral Route Increases Paracetamol Efficacy. Clin Drug
- 303 Investig. 1997;14(6): 474-481.
- 14. Soulier SM, Page JC, Larsen LC, Grose BC. The efficacy of ANSAID (flurbiprofen) as an
- analgesic in foot surgery. J Foot Ankle Surg. 1997;36(6): 414-417.

- 306 15. Whelton A, Lefkowith JL, West CR, Verburg KM. Cardiorenal effects of celecoxib as
- compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney
- 308 Int. 2006;70(8): 1495-502.
- 309 16. Schmidt M, Sørensen HT, Pedersen L. Diclofenac use and cardiovascular risks: series of
- nationwide cohort studies. BMJ. 2018;362: k3426.
- 311 17. Mitra S, Khandelwal P, Sehgal A. Diclofenac-tramadol vs. diclofenac-acetaminophen
- combinations for pain relief after caesarean section. Acta Anaesthesiol Scand. 2012;56(6):
- 313 706-711.
- 18. Shareef SM, Sridhar I, Dakshayani KM, Rao YV, Santhamma B. Evaluation of the effects of
- tramadol and diclofenac alone and in combination on post-cesarean pain. Int J Basic Clin
- 316 Pharmacol [Internet]. 2017;3(3): 470-473.
- 317 19. Wilder-Smith CH, Hill L, Dyer RA, Torr G, Coetzee E. Postoperative sensitization and pain
- after cesarean delivery and the effects of single im doses of tramadol and diclofenac alone and
- in combination. Anesth Analg. 2003;97(2): 526-533.
- 20. Cossmann M, Kohnen C, Langford R, McCartney C. [Tolerance and safety of tramadol use.
- Results of international studies and data from drug surveillance]. Drugs. 1997;53 Suppl 2: 50-
- 322 62.
- 323 21. Hallberg P, Brenning G. Angioedema induced by tramadol—a potentially life-threatening
- 324 condition. Eur J Clin Pharmacol. 2005;60(12): 901-903.
- 325 22. Dhingra H. Naproxen; 2022 [cited 2023 March 27]. Available from:
- 326 https://www.buzzrx.com/naproxen-coupon/side-effects.
- 327 23. Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, et al. Effect of Opioid
- vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or

- Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. JAMA.
- 330 2018;319(9): 872-882.
- 331 24. Sutton LB. Naproxen sodium. J Am Pharm Assoc (Wash). 1996;Ns36(11):663-7.
- 25. Al-Abri SA, Anderson IB, Pedram F, Colby JM, Olson KR. Massive naproxen overdose with
- serial serum levels. J Med Toxicol. 2015;11(1): 102-105.
- 26. Finnerup NB, Jensen TS. Clinical use of pregabalin in the management of central neuropathic
- pain. Neuropsychiatr Dis Treat. 2007;3(6): 885-891.
- 27. Ho JM, Macdonald EM, Luo J, Gomes T, Antoniou T, Mamdani MM, et al. Pregabalin and
- heart failure: A population-based study. Pharmacoepidemiol Drug Saf. 2017;26(9): 1087-
- 338 1092.
- 28. Park YS, Kim YB, Kim JM. Status epilepticus caused by nefopam. J Korean Neurosurg Soc.
- 340 2014;56(5): 448-450.
- 341 29. Zhang Y, He B, Zhao J, Zhang M, Ren Q, Zhang W, et al. Addition of Celebrex and Pregabalin
- to Ropivacaine for Posterior Spinal Surgery: A Randomized, Double-Blinded, Placebo-
- Controlled Trial. Drug Des Devel Ther. 2021;15: 735-742.
- 30. Barcella C, Lamberts M, McGettigan P, Fosbøl E, Lindhardsen J, Torp-Pedersen C, et al.
- Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy—A
- nationwide study in patients with osteoarthritis. Basic Clin Pharmacol Toxicol. 2018;124.
- 31. Searle. Product Information. Celebrex (celecoxib); 2001 [cited 2023 October 18]. Available
- from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20998s10lbl.pdf.
- 32. Khalil NY, Aldosari KF. Meloxicam. Profiles Drug Subst Excip Relat Methodol. 2020;45:
- 350 159-197.

- 33. Poverennova IE, Zolotovskaya IA. [Cerebrovascular risks and prediction of complications in
- patients with backache during therapy with nonsteroidal anti-inflammatory drugs]. Ter Arkh.
- 353 2015;87(5): 53-57.
- 34. Dalal D, Dubreuil M, Peloquin C, Neogi T, Zhang Y, Choi H, et al. Meloxicam and risk of
- myocardial infarction: a population-based nested case-control study. Rheumatol Int.
- 356 2017;37(12): 2071-2078.
- 35. Arnao V, Riolo M, Fierro B, Aridon P. Seizure following the Use of the COX-2 Inhibitor
- 358 Etoricoxib. Case Rep Neurol Med. 2017;2017: 1410759.
- 36. Baraf HS, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, Soffer B, et al. Gastrointestinal
- side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus
- Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J
- Rheumatol. 2007;34(2): 408-420.
- 363 37. Drugbank. Etoricoxib; 2021 [cited 2023 December 01]. [Entry 366]. Available from:
- https://go.drugbank.com/drugs/DB01628.
- 365 38. Thumtecho S, Wainipitapong S, Tantakitti P. Transient depersonalisation/derealisation
- syndrome from tramadol. BMJ Case Rep. 2023;16(6): e254909.
- 39. Hassab ARM, Fawzy HM, Elfawal SM, Kamaleldin DM. Comparative study between
- paracetamol versus paracetamol and pregabalin combination for postoperative analgesia in
- hip surgeries. QJM: Int J Med. 2020;113(Supplement 1).
- 40. Hyllested M, Jones S, Pedersen JL, Kehlet H. Comparative effect of paracetamol, NSAIDs or
- their combination in postoperative pain management: a qualitative review. Br J Anaesth.
- 372 2002;88(2): 199-214.

- 373 41. Verkleij SP, Luijsterburg PA, Bohnen AM, Koes BW, Bierma-Zeinstra SM. NSAIDs vs
- acetaminophen in knee and hip osteoarthritis: a systematic review regarding heterogeneity
- influencing the outcomes. Osteoarthr Cartil. 2011;19(8): 921-929.
- 42. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal
- antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation.
- 378 2006;113(12): 1578-1587.
- 379 43. Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic
- analgesic use and decline in renal function in women. Arch Intern Med. 2004;164(14): 1519-
- 381 1524.
- 382 44. Pezzia C, Sanders C, Welch S, Bowling A, Lee WM. Psychosocial and behavioral factors in
- acetaminophen-related acute liver failure and liver injury. J Psychosom Res. 2017;101: 51-
- 384 57.
- 385 45. Lee BT, Odin JA, Grewal P. An Approach to Drug-Induced Liver Injury from the Geriatric
- Perspective. Curr Gastroenterol Rep. 2021;23(4): 6.
- 387 46. Zyoud SH, Awang R, Sulaiman SA, Al-Jabi SW. Association between gastrointestinal
- manifestations following acetaminophen poisoning and outcome in 291 acetaminophen
- poisoning patients. Pharmacoepidemiol Drug Saf. 2010;19(5): 511-517.
- 390 47. Brown G. Acetaminophen-induced hypotension. Heart Lung. 1996;25(2): 137-140.
- 391 48. Danguy des Déserts M, Nguyen BV, Giacardi C, Commandeur D, Paleiron N.
- [Acetaminophen-induced hypotension after intravenous and oral administration]. Ann Fr
- 393 Anesth Reanim. 2010;29(4): 313-314.




Figure 1




Figure 2